McKesson Partners with Apollo Funds for MMS Stake Sale
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 20 2026
0mins
Source: NASDAQ.COM
- Strategic Milestone: McKesson Corporation announced a deal with Apollo Funds to sell a minority stake in its Medical-Surgical Solutions (MMS) business, marking a significant milestone in its separation strategy in preparation for a planned initial public offering (IPO).
- Significant Investment: Apollo Funds will invest $1.25 billion in convertible preferred equity of MMS to acquire approximately 13% minority interest, valuing MMS at around $13 billion, reflecting strong market confidence in the business.
- Positive Market Reaction: This transaction not only provides McKesson with financial support but also strengthens its market position in the healthcare sector, expected to drive future growth and enhance investor confidence.
- Future Development Potential: By partnering with Apollo Funds, McKesson can accelerate the independent growth of MMS, further optimizing its business structure and laying a solid foundation for the upcoming IPO to attract more investor interest.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MCK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MCK
Wall Street analysts forecast MCK stock price to rise
14 Analyst Rating
12 Buy
2 Hold
0 Sell
Strong Buy
Current: 807.330
Low
880.00
Averages
942.83
High
1000.00
Current: 807.330
Low
880.00
Averages
942.83
High
1000.00
About MCK
McKesson Corporation is a diversified healthcare services company, which focuses on advancing health outcomes for patients everywhere. Its U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products in the United States (U.S.). The Prescription Technology Solutions (RxTS) segment helps solve medication access, affordability and adherence challenges for patients by working across healthcare to connect patients, pharmacies, pharmacy benefit managers, health plans, and biopharma companies. The Medical-Surgical Solutions provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, hospital reference labs, and home healthcare agencies. The International segment provides distribution and services to wholesale, institutional, and retail customers in Canada and Norway. It also offers oncology and specialty solutions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
PVAL Stock Price Analysis and ETF Dynamics
- Price Fluctuation Analysis: PVAL's 52-week low is $39.71 and high is $52.1295, with the current trading price at $51.42, indicating that the stock is fluctuating near its high, which may influence investor buying decisions.
- Technical Analysis Tool: Comparing the current stock price to the 200-day moving average can provide valuable insights for investors, helping to assess market trends and potential buying opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors are buying and selling 'units' that can be created or destroyed based on investor demand, impacting the liquidity and market performance of the ETF.
- Liquidity Monitoring: Weekly monitoring of changes in ETF shares outstanding focuses on notable inflows or outflows, where inflows necessitate the purchase of underlying assets, while outflows may lead to the sale of these assets, affecting the prices of related stocks.
See More
Amgen vs Iovance: Investment Comparison
- Amgen's Stability: In FY 2025, Amgen reported nearly $36.7 billion in revenue, a 9.9% increase year-over-year, with a net income of approximately $7.7 billion and a net margin of about 21%, showcasing its strong profitability and stability in the global market.
- Iovance's Rapid Growth: Iovance achieved approximately $263.5 million in revenue for FY 2025, marking a 60.6% increase, yet it reported a net loss of nearly $391 million, indicating its innovative potential in cancer treatment but highlighting its lack of profitability.
- Risk Comparison: Amgen faces risks from government pricing regulations and competition from biosimilars, while Iovance must navigate the complexities of manufacturing personalized therapies and uncertainties regarding market adoption, which could impact their future market performance.
- Valuation Differences: Amgen has a forward P/E ratio of 15.1, reflecting its value as a mature company, whereas Iovance, still unprofitable, has a P/S ratio of 5.4, indicating its high-risk investment profile in the early growth stage.
See More
Cardinal Health Continues Growth with Stock Price Surge
- Outstanding Stock Performance: Cardinal Health achieved a remarkable 74% stock price increase in 2025, followed by a 7.9% rise year-to-date in 2026, reflecting sustained investor confidence in its growth strategy, significantly outperforming peers McKesson and Cencora.
- Enhanced Profitability: In its fiscal Q3 2026 earnings report, the company reported a 35% EPS growth and raised its earnings guidance again, underscoring management's confidence in sustained operational momentum despite macro uncertainties and pricing pressures.
- Strong Specialty Pharmaceutical Business: Cardinal Health's Pharmaceutical and Specialty Solutions segment saw an 11% revenue increase to $56.1 billion and an 18% profit rise in Q3, with expectations for specialty sales to exceed $50 billion in fiscal 2026, indicating robust growth potential in the market.
- Rapid Expansion of New Businesses: The company's
See More
IYK ETF 52-Week Price Range Analysis
- Price Fluctuation Analysis: The IYK ETF has a 52-week low of $65.21 and a high of $77.70, with the last trade at $73.34, indicating stability within its trading range that may attract investor interest.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average provides valuable insights for investors, aiding in market trend assessment and potential buying opportunities.
- ETF Unit Trading Mechanism: ETFs trade similarly to stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in ETF shares outstanding highlights significant inflows (new units created) or outflows (old units destroyed), which can affect the underlying stocks held by the ETF and influence overall market dynamics.
See More
Market Dynamics and Investment Strategy Analysis
- Market Opening Outlook: Following President Trump's remarks about Iran's delay in peace negotiations, stocks are expected to open lower, with rising oil prices; although the May consumer price index met expectations, the market's anticipation of a Fed interest rate hike indicates investor caution regarding future economic conditions.
- SpaceX IPO Activity: As investors liquidate stock positions to buy into the SpaceX IPO, this trend is expected to intensify ahead of Friday's trading start, with the need for rebalancing in the Nasdaq 100 index making large-cap companies significant contributors, reflecting strong market interest in emerging tech firms.
- Enterprise Model Launch: Anthropic unveiled its high-powered enterprise model, Claude Fable 5, based on Mythos, promising a measured release approach due to its effectiveness in identifying security flaws, showcasing the company's innovative potential in the AI sector.
- Analyst Rating Changes: Evercore ISI upgraded Entergy from hold to buy, raising the price target from $115 to $121, as analysts expressed confidence in the management's ability to attract significant demand, reflecting an optimistic outlook for the electric power industry.
See More
McKesson Reports Strong Q4 2026 Earnings with Strategic Growth Plans
- Strong Financial Performance: McKesson reported an adjusted earnings per diluted share of $11.69 for Q4 2026, with consolidated revenues increasing by 6% to $96.3 billion and gross profit rising by 14% to $3.9 billion, indicating robust market performance and profitability.
- Shareholder Return Initiatives: The company returned $5.1 billion to shareholders through share repurchases in fiscal 2026 and anticipates free cash flow to remain between $4.5 billion and $4.9 billion in fiscal 2027, reflecting management's confidence in future cash generation and commitment to shareholders.
- Separation Progress: McKesson is advancing its plan to spin off its Medical-Surgical Solutions segment into an independent entity, having secured a $1.25 billion strategic investment from Apollo, which is expected to unlock shareholder value and enhance strategic clarity.
- Future Growth Outlook: The company projects adjusted earnings per diluted share in the range of $43.80 to $44.60 for fiscal 2027, with revenue growth expectations of 14.5% to 18.5% in the oncology and multispecialty segment, showcasing a positive outlook on new market opportunities.
See More
PVAL Stock Price Analysis and ETF Dynamics
- Price Fluctuation Analysis: PVAL's 52-week low is $39.71 and high is $52.1295, with the current trading price at $51.42, indicating that the stock is fluctuating near its high, which may influence investor buying decisions.
- Technical Analysis Tool: Comparing the current stock price to the 200-day moving average can provide valuable insights for investors, helping to assess market trends and potential buying opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors are buying and selling 'units' that can be created or destroyed based on investor demand, impacting the liquidity and market performance of the ETF.
- Liquidity Monitoring: Weekly monitoring of changes in ETF shares outstanding focuses on notable inflows or outflows, where inflows necessitate the purchase of underlying assets, while outflows may lead to the sale of these assets, affecting the prices of related stocks.
See More
Amgen vs Iovance: Investment Comparison
- Amgen's Stability: In FY 2025, Amgen reported nearly $36.7 billion in revenue, a 9.9% increase year-over-year, with a net income of approximately $7.7 billion and a net margin of about 21%, showcasing its strong profitability and stability in the global market.
- Iovance's Rapid Growth: Iovance achieved approximately $263.5 million in revenue for FY 2025, marking a 60.6% increase, yet it reported a net loss of nearly $391 million, indicating its innovative potential in cancer treatment but highlighting its lack of profitability.
- Risk Comparison: Amgen faces risks from government pricing regulations and competition from biosimilars, while Iovance must navigate the complexities of manufacturing personalized therapies and uncertainties regarding market adoption, which could impact their future market performance.
- Valuation Differences: Amgen has a forward P/E ratio of 15.1, reflecting its value as a mature company, whereas Iovance, still unprofitable, has a P/S ratio of 5.4, indicating its high-risk investment profile in the early growth stage.
See More
Cardinal Health Continues Growth with Stock Price Surge
- Outstanding Stock Performance: Cardinal Health achieved a remarkable 74% stock price increase in 2025, followed by a 7.9% rise year-to-date in 2026, reflecting sustained investor confidence in its growth strategy, significantly outperforming peers McKesson and Cencora.
- Enhanced Profitability: In its fiscal Q3 2026 earnings report, the company reported a 35% EPS growth and raised its earnings guidance again, underscoring management's confidence in sustained operational momentum despite macro uncertainties and pricing pressures.
- Strong Specialty Pharmaceutical Business: Cardinal Health's Pharmaceutical and Specialty Solutions segment saw an 11% revenue increase to $56.1 billion and an 18% profit rise in Q3, with expectations for specialty sales to exceed $50 billion in fiscal 2026, indicating robust growth potential in the market.
- Rapid Expansion of New Businesses: The company's
See More
IYK ETF 52-Week Price Range Analysis
- Price Fluctuation Analysis: The IYK ETF has a 52-week low of $65.21 and a high of $77.70, with the last trade at $73.34, indicating stability within its trading range that may attract investor interest.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average provides valuable insights for investors, aiding in market trend assessment and potential buying opportunities.
- ETF Unit Trading Mechanism: ETFs trade similarly to stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in ETF shares outstanding highlights significant inflows (new units created) or outflows (old units destroyed), which can affect the underlying stocks held by the ETF and influence overall market dynamics.
See More
Market Dynamics and Investment Strategy Analysis
- Market Opening Outlook: Following President Trump's remarks about Iran's delay in peace negotiations, stocks are expected to open lower, with rising oil prices; although the May consumer price index met expectations, the market's anticipation of a Fed interest rate hike indicates investor caution regarding future economic conditions.
- SpaceX IPO Activity: As investors liquidate stock positions to buy into the SpaceX IPO, this trend is expected to intensify ahead of Friday's trading start, with the need for rebalancing in the Nasdaq 100 index making large-cap companies significant contributors, reflecting strong market interest in emerging tech firms.
- Enterprise Model Launch: Anthropic unveiled its high-powered enterprise model, Claude Fable 5, based on Mythos, promising a measured release approach due to its effectiveness in identifying security flaws, showcasing the company's innovative potential in the AI sector.
- Analyst Rating Changes: Evercore ISI upgraded Entergy from hold to buy, raising the price target from $115 to $121, as analysts expressed confidence in the management's ability to attract significant demand, reflecting an optimistic outlook for the electric power industry.
See More
McKesson Reports Strong Q4 2026 Earnings with Strategic Growth Plans
- Strong Financial Performance: McKesson reported an adjusted earnings per diluted share of $11.69 for Q4 2026, with consolidated revenues increasing by 6% to $96.3 billion and gross profit rising by 14% to $3.9 billion, indicating robust market performance and profitability.
- Shareholder Return Initiatives: The company returned $5.1 billion to shareholders through share repurchases in fiscal 2026 and anticipates free cash flow to remain between $4.5 billion and $4.9 billion in fiscal 2027, reflecting management's confidence in future cash generation and commitment to shareholders.
- Separation Progress: McKesson is advancing its plan to spin off its Medical-Surgical Solutions segment into an independent entity, having secured a $1.25 billion strategic investment from Apollo, which is expected to unlock shareholder value and enhance strategic clarity.
- Future Growth Outlook: The company projects adjusted earnings per diluted share in the range of $43.80 to $44.60 for fiscal 2027, with revenue growth expectations of 14.5% to 18.5% in the oncology and multispecialty segment, showcasing a positive outlook on new market opportunities.
See More
